Review article: Explaining risks of inflammatory bowel disease therapy to patients

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 1, 2011, Pages 23-32

  Siegel, C A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ACNE; ADRENAL DISEASE; ALLERGIC REACTION; ANKLE EDEMA; AVASCULAR NECROSIS; CATARACT; COMBINATION CHEMOTHERAPY; CONFUSION; CROHN DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FACE EDEMA; FATIGUE; HEPATITIS; HIP INJURY; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; LEUKOENCEPHALOPATHY; LIVER FUNCTION TEST; LONG TERM CARE; LUPUS LIKE SYNDROME; MEMORY DISORDER; MONOTHERAPY; NAUSEA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OUTCOMES RESEARCH; PANCREATITIS; PATIENT ATTITUDE; PATIENT DECISION MAKING; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SKIN BRUISING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; COMBINED MODALITY THERAPY; COMMUNICATION; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; RISK FACTORS;

EID: 78650000245     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04489.x     Document Type: Review

References (52)

1. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
2. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
3. Lipkus IM,. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making 2007; 27: 696-713.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ,. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
5. Present DH,. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 48-57.
6. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5. (Pubitemid 24289711)
7. Rutgeerts PJ,. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1515-25.
8. Siegel CA,. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 2010 [Epub ahead of print].
9. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J,. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6.
10. Siegel CA, Siegel LS, Hyams J, et al. A real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2010 [Epub ahead of print].
11. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
12. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD,. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5.
13. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 72-7.
14. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-7.
15. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32.
16. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ,. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10: 369-75.
17. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL,. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 3150-6.
18. Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127: 356-64.
19. Bohon P, Dugernier T, Debongnie JC, Pirenne B,. Hypersensitivity interstitial pneumopathy and ulcero-hemorrhagic rectocolitis: role of methotrexate. Acta Gastroenterol Belg 1993; 56: 352-7.
20. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR,. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
21. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514-9.
22. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L,. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16: 254-61.
23. Siegel CA,. Comprehensive approach to patient risk: risk versus benefit of biologics and immune suppressants. In:, Targan S, Shanahan F, Karp L, eds. Inflammatory Bowel Disease: Translating Basic Science into Clinical Practice. Oxford, UK: Wiley-Blackwell, 2010: 678-92.
24. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9.
25. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE,. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-24.
26. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
27. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE,. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-81.
28. Data on file. Malvern, PA: Centocor, Inc., 2010.
29. Feagan BG, McDonald J, Ponich T, et al. Combination of maintenance methotrexate-infliximab trial (COMMIT). Digestive Disease Week, May, 2008; Abstract 682C.
30. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
31. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
32. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-8.
33. Data on file, Elan, San Francisco, CA, 2010.
34. Schwartz LM, Woloshin S, Black WC, Welch HG,. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997; 127: 966-72.
35. Sheridan SL, Pignone M,. Numeracy and the medical student's ability to interpret data. Eff Clin Pract 2002; 5: 35-40.
36. Hux JE, Naylor CD,. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making 1995; 15: 152-7.
37. Sheridan SL, Pignone MP, Lewis CL,. A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats. J Gen Intern Med 2003; 18: 884-92.
38. Covey J,. A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Making 2007; 27: 638-54.
39. Fagerlin A, Ubel PA, Smith DM, Zikmund-Fisher BJ,. Making numbers matter: present and future research in risk communication. Am J Health Behav 2007; 31 (Suppl. 1): S47-56.
40. Peters E, Hibbard J, Slovic P, Dieckmann N,. Numeracy skill and the communication, comprehension, and use of risk-benefit information. Health Aff (Millwood) 2007; 26: 741-8.
41. Berry DC, Raynor DK, Knapp P, Bersellini E,. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 2003; 26: 1-11.
42. Han PK, Klein WM, Lehman TC, Massett H, Lee SC, Freedman AN,. Laypersons' responses to the communication of uncertainty regarding cancer risk estimates. Med Decis Making 2009; 29: 391-403.
43. Han PK, Klein WM, Lehman T, Killam B, Massett H, Freedman AN,. Communication of uncertainty regarding individualized cancer risk estimates: effects and influential factors. Med Decis Making 2010 [Epub ahead of print].
44. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133: 769-79.
45. Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE,. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal 2009; 29: 121-36.
46. Bernstein KI, Promislow S, Carr R, Rawsthorne P, Walker JR, Bernstein CN,. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis 2010 [Epub ahead of print].
47. Reyna VF,. A theory of medical decision making and health: fuzzy trace theory. Med Decis Making 2008; 28: 850-65.
48. Hibbard JH, Peters E, Dixon A, Tusler M,. Consumer competencies and the use of comparative quality information: it isn't just about literacy. Med Care Res Rev 2007; 64: 379-94.
49. Baars JE, Markus T, Kuipers EJ, Van Der Woude CJ,. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010; 81: 113-9.
50. Baars JE, Siegel CA, Kuipers EJ, Van der Woude CJ,. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion 2009; 79: 30-5.
51. Siegel CA, Levy LC, Mackenzie TA, Sands BE,. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1-6.
52. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1428-35.